{"id":"https://openalex.org/W2516435552","doi":"https://doi.org/10.1212/wnl.0000000000003118","title":"Adjunctive pregabalin vs gabapentin for focal seizures","display_name":"Adjunctive pregabalin vs gabapentin for focal seizures","publication_year":2016,"publication_date":"2016-08-13","ids":{"openalex":"https://openalex.org/W2516435552","doi":"https://doi.org/10.1212/wnl.0000000000003118","mag":"2516435552","pmid":"https://pubmed.ncbi.nlm.nih.gov/27521437","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5035985"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000003118","doi":"https://doi.org/10.1212/wnl.0000000000003118","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000003118","pdf_url":"https://n.neurology.org/content/neurology/87/12/1242.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://n.neurology.org/content/neurology/87/12/1242.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038885649","display_name":"Jacqueline A. French","orcid":"https://orcid.org/0000-0003-2242-8027","observed_orcids":["https://orcid.org/0000-0003-2242-8027"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":true,"raw_author_name":"Jacqueline French","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022110262","display_name":"Paul Glue","orcid":"https://orcid.org/0000-0002-7305-2800","observed_orcids":["https://orcid.org/0000-0002-7305-2800"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Paul Glue","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071565453","display_name":"Daniel J. Friedman","orcid":"https://orcid.org/0000-0003-1068-1797","observed_orcids":["https://orcid.org/0000-0003-1068-1797","https://orcid.org/0000-0002-3442-7454"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Daniel Friedman","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109337386","display_name":"Mary Almas","orcid":"https://orcid.org/0009-0003-1077-7307","observed_orcids":["https://orcid.org/0009-0003-1077-7307"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Mary Almas","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000391971","display_name":"Nandan Yardi","orcid":"https://orcid.org/0000-0001-6096-5398","observed_orcids":["https://orcid.org/0000-0001-6096-5398"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Nandan Yardi","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040362413","display_name":"Lloyd E. Knapp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Lloyd Knapp","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045036945","display_name":"Verne W. Pitman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Verne Pitman","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079245562","display_name":"Holly B. Posner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]},{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ","US"],"is_corresponding":false,"raw_author_name":"Holly B. Posner","raw_affiliation_strings":["From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY; Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand; Global Product Development, Pfizer Inc. (M.A., H.B.P.), New York, NY; Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India; and Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I57206974","https://openalex.org/I80281795"]},{"raw_affiliation_string":"Department of Psychological Medicine, Dunedin School of Medicine, University of Otago (P.G.), New Zealand","institution_ids":["https://openalex.org/I80281795"]},{"raw_affiliation_string":"From the NYU Comprehensive Epilepsy Center (J.F., D.F.), New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]},{"raw_affiliation_string":"Global Product Development, Pfizer Inc. (L.K., V.P.), Groton, CT","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Yardi Epilepsy Clinic, KEM and Vatsal Hospital (N.Y.), Pune, India","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5038885649"],"corresponding_institution_ids":["https://openalex.org/I180857899","https://openalex.org/I4210086933","https://openalex.org/I57206974","https://openalex.org/I80281795"],"apc_list":null,"apc_paid":null,"fwci":1.7832,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.83810982,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"87","issue":"12","first_page":"1242","last_page":"1249"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pregabalin","display_name":"pregabalin","score":1.0},{"id":"https://openalex.org/keywords/gabapentin","display_name":"gabapentin","score":1.0},{"id":"https://openalex.org/keywords/adjunctive-antiepileptic-therapy","display_name":"adjunctive antiepileptic therapy","score":0.921999990940094},{"id":"https://openalex.org/keywords/focal-seizures","display_name":"focal seizures","score":0.906000018119812},{"id":"https://openalex.org/keywords/drug-resistant-epilepsy","display_name":"drug-resistant epilepsy","score":0.871999979019165},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.8629999756813049},{"id":"https://openalex.org/keywords/comparative-efficacy","display_name":"drug efficacy comparison","score":0.8029999732971191},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8180000185966492},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C2776468701","wikidata":"https://www.wikidata.org/wiki/Q412174","display_name":"Pregabalin","level":2,"score":0.9872913956642151},{"id":"https://openalex.org/C2776608144","wikidata":"https://www.wikidata.org/wiki/Q410352","display_name":"Gabapentin","level":3,"score":0.9510371088981628},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7866836190223694},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5763482451438904},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5713567733764648},{"id":"https://openalex.org/C3018162438","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Adjunctive treatment","level":2,"score":0.5692781805992126},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5527351498603821},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.4856054186820984},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4517601430416107},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4449203908443451},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.42163974046707153},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.41693273186683655},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32229307293891907},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.06648463010787964},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000069279","descriptor_name":"Drug Resistant Epilepsy","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000069583","descriptor_name":"Pregabalin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069583","descriptor_name":"Pregabalin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077206","descriptor_name":"Gabapentin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000588","descriptor_name":"Amines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000588","descriptor_name":"Amines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003509","descriptor_name":"Cyclohexanecarboxylic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003509","descriptor_name":"Cyclohexanecarboxylic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004828","descriptor_name":"Epilepsies, Partial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005680","descriptor_name":"gamma-Aminobutyric Acid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005680","descriptor_name":"gamma-Aminobutyric Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012640","descriptor_name":"Seizures","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1212/wnl.0000000000003118","doi":"https://doi.org/10.1212/wnl.0000000000003118","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000003118","pdf_url":"https://n.neurology.org/content/neurology/87/12/1242.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5035985","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5035985","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Text"},{"id":"pmid:27521437","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27521437","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1212/wnl.0000000000003118","doi":"https://doi.org/10.1212/wnl.0000000000003118","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000003118","pdf_url":"https://n.neurology.org/content/neurology/87/12/1242.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2516435552.pdf","grobid_xml":"https://content.openalex.org/works/W2516435552.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W1554576051","https://openalex.org/W1576891234","https://openalex.org/W1707138741","https://openalex.org/W1975404751","https://openalex.org/W1988098024","https://openalex.org/W1999820418","https://openalex.org/W2025181667","https://openalex.org/W2062160060","https://openalex.org/W2099478180","https://openalex.org/W2113931315","https://openalex.org/W2116965417","https://openalex.org/W2138521331","https://openalex.org/W2168120312","https://openalex.org/W2169015200","https://openalex.org/W4236676256","https://openalex.org/W4255480113"],"related_works":["https://openalex.org/W2151789027","https://openalex.org/W2041426021","https://openalex.org/W2062160060","https://openalex.org/W2090188920","https://openalex.org/W1982833073","https://openalex.org/W2147244904","https://openalex.org/W2010549507","https://openalex.org/W2059212626","https://openalex.org/W2162748306","https://openalex.org/W2079160239"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,78,88,118,148,184,197,202,257,261],"comparative":[4,36,220],"safety":[5,39],"and":[6,11,38,43,60,69,124,133,139,141,175,196],"adjunctive":[7,46],"efficacy":[8,28,37,186,221],"of":[9,34,41,94,183,191,201,256,263],"pregabalin":[10,42,100,138,245],"gabapentin":[12,44,105,250],"in":[13,17,48,83,126,218,242,251],"reducing":[14,252],"seizure":[15,85,253],"frequency":[16],"patients":[18,96,112,237],"with":[19,50,177,238],"partial-onset":[20,52],"seizures":[21,53,240],"based":[22,188],"on":[23,189],"prestudy":[24],"modeling":[25,190],"showing":[26],"superior":[27,248],"for":[29,137,145,236],"pregabalin.":[30],"METHODS:":[31],"The":[32,63,74,121,158,181],"design":[33],"this":[35,243,264],"study":[40,64,230,265],"as":[45],"treatment":[47,72,89,119],"adults":[49],"refractory":[51],"was":[54,77,131,152,163],"randomized,":[55],"flexible":[56],"dose,":[57],"double":[58],"blind,":[59],"parallel":[61],"group.":[62],"included":[65],"a":[66,70],"6-week":[67],"baseline":[68,82,130],"21-week":[71],"phase.":[73,90,120],"primary":[75,149],"endpoint":[76],"percentage":[79,127],"change":[80,128],"from":[81,129],"28-day":[84],"rate":[86],"to":[87,99,169,216,249,269],"RESULTS:":[91],"A":[92],"total":[93],"484":[95],"were":[97,173,206],"randomized":[98],"(n":[101,106],"=":[102,107],"242)":[103],"or":[104],"242).":[108],"Of":[109],"these,":[110],"359":[111],"(187":[113],"pregabalin,":[114],"172":[115],"gabapentin)":[116],"completed":[117],"observed":[122],"median":[123,161],"mean":[125],"-58.65":[132],"-47.7":[134],"(SD":[135,143],"48.3)":[136],"-57.43":[140],"-45.28":[142],"60.6)":[144],"gabapentin.":[146],"For":[147],"endpoint,":[150],"there":[151],"no":[153],"significant":[154],"difference":[155,162,187],"between":[156],"treatments.":[157],"Hodges-Lehman":[159],"estimated":[160],"0.0":[164],"(95%":[165],"confidence":[166],"interval":[167],"-6.0":[168],"7.0).":[170],"Safety":[171],"profiles":[172],"comparable":[174],"consistent":[176],"prior":[178],"trials.":[179,222],"CONCLUSIONS:":[180],"absence":[182],"anticipated":[185],"prior,":[192],"nearly":[193],"identical":[194],"trials":[195],"larger-than-expected":[198],"response":[199,259],"rates":[200],"2":[203],"antiepileptic":[204],"drugs":[205],"unexpected.":[207],"These":[208],"findings":[209],"raise":[210],"questions":[211],"that":[212,235],"are":[213,266],"potentially":[214],"important":[215],"consider":[217],"future":[219],"CLINICALTRIALSGOV":[223],"IDENTIFIER:":[224],"NCT00537940.":[225],"CLASSIFICATION":[226],"OF":[227],"EVIDENCE:":[228],"This":[229],"provides":[231],"Class":[232],"II":[233],"evidence":[234],"partial":[239],"enrolled":[241],"study,":[244],"is":[246],"not":[247],"frequency.":[254],"Because":[255],"atypical":[258],"rates,":[260],"results":[262],"poorly":[267],"generalizable":[268],"other":[270],"epilepsy":[271],"populations.":[272]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-09-16T00:00:00"}